Vaccine

Press Release: Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs

Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs Late-breaking data show infant...

MOBILion Systems to Highlight Customer Use Cases from its MOBIE® Platform and Unveil Plans for their Next Generation Proteomics Platform at ASMS 2025

CHADDS FORD, Pa., May 27, 2025 /PRNewswire/ -- MOBILion Systems, Inc., a leader in separation science innovation, will attend and...

Mangoceuticals’ Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian Flu

Dallas, TX, May 27, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on...

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with improved pathologic response.ROCHESTER, N.Y., May 27,...

BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting

MAINZ, Germany, May 27, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data from select pipeline candidates...

IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025

Presentation at ESMO will follow oral 2025 ASCO Annual Meeting presentation highlighting unprecedented survival data from Phase 2 OVATION 2...

Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction

Investigator-initiated Phase 2 trial to evaluate TNX-102 SL’s potential to reduce severity of acute stress reaction (ASR) and frequency of...

GenVivo Highlights Non-Integrating Retroviral Vector Technology with Persistent Payload Expression at the 2025 Retroviruses Meeting

Retroviral vectors that are both non-replicating and non-integrating represent a novel and attractive tool that has potential advantages for gene...

Brain Cancer Canada Awards $68,000 Research Grant for Clinical Trial of Anti-Cancer Vaccine Targeting DIPG, the Most Aggressive Pediatric Brain Cancer

TORONTO, May 17, 2025 (GLOBE NEWSWIRE) -- Today, on DIPG Awareness Day, Brain Cancer Canada is pleased to award $68,000...

error: Content is protected !!